Listing 3 - Actual negotiations

Indication:

Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, in adult patients who are not eligible for autologous stem cell transplant & have received at least one prior therapy (In combination with bendamustine & rituximab)

Indication:

Psoriasis, moderate to severe plaque

Indication:

Chronic weight management

Indication:

Severe Hypoglycemia

Indication:

Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT

Indication:

Heart failure, NYHA class II or III

Indication:

Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma

Indication:

Secondary Progressive Multiple Sclerosis (SPMS)

Indication:

Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy

Indication:

Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)